Phase 1 single ascending dose study of ARGX-113 in healthy volunteers
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 25 Aug 2016
At a glance
- Drugs ARGX 113 (Primary)
- Indications Myasthenia gravis
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 25 Aug 2016 According to an arGEN-X media release, complete data set from the study will be presented at argenx R&D day, 22 September 2016.
- 09 Jan 2016 New trial record
- 05 Jan 2016 According to an arGEN-X media release, the dose-escalation part of this study has been completed.